University of Pennsylvania
Welcome,         Profile    Billing    Logout  
 1613 Trials 
1993 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kampman, Kyle
NCT05028062: Naltrexone in AUD Reward Drinkers

Recruiting
4
60
US
XR-NTX 380 mg, intramuscular injection, Vivitrol naltrexone for extended-release injectable suspension, Medical Management, Placebo intramuscular injection, Inactive placebo
University of Pennsylvania, Alkermes, Inc.
Alcohol Use Disorder, Alcoholism
11/25
11/26
Tebas, Pablo
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

Not yet recruiting
2
99
US
GLS-1200, Placebo, Sterile Saline
GeneOne Life Science, Inc.
Sinusitis Chronic
12/23
09/24
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Completed
2
75
US
Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
04/24
04/24
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22
NCT03705169: Pharmacokinetics and Safety of SAR441236

Terminated
1
52
US
SAR441236, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics
HIV-1-infection
04/22
04/22
NCT05293249: dMAbs for Prevention of COVID-19

Active, not recruiting
1
61
US
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals
Healthy Volunteers
09/25
09/25
Frank, Ian
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Active, not recruiting
1
95
US, RoW
VIR-1388, Placebo
Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network
HIV I Infection
11/25
11/27
Donato, Michele L
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol

Available
2/3
40
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
 
 
NCT04220190: RAPA-501 Therapy for ALS

Recruiting
2/3
41
US
RAPA-501 Autologous T cells, RAPA-501 cells
Rapa Therapeutics LLC, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/26
06/27
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Philip, Philip A
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Recruiting
2
120
Europe, Japan, US, RoW
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
12/26
12/26
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
Brem, Steven
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

Available
N/A
US
DCVax-L
Northwest Biotherapeutics
GBM, Glioblastoma Multiforme
 
 
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Maki, Robert
NCT04551430: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting
2
105
US
Cabozantinib, Nivolumab, Opdivo, Ipilimumab, Yervoy
Washington University School of Medicine, Exelixis, Bristol-Myers Squibb
Metastatic Soft-tissue Sarcoma
06/24
06/30
SARC037, NCT04067115: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients

Active, not recruiting
1/2
48
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
06/25
06/25
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
Vaishampayan, Ulka N
NUTRA, NCT03421652: Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

Completed
2
20
US
Nivolumab, 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation
Barbara Ann Karmanos Cancer Institute, Bristol-Myers Squibb
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
03/23
03/23
PLANE-PC, NCT04848337: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Recruiting
2
50
US
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
University of Michigan Rogel Cancer Center, Merck Sharp & Dohme LLC, Hoosier Cancer Research Network
Prostate Cancer Metastatic, Neuroendocrine Tumors
12/24
12/24
NCI-2012-01247, NCT01684397: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Active, not recruiting
1/2
51
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, GW786034B, Votrient, Pharmacological Study
Roswell Park Cancer Institute, GlaxoSmithKline
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
05/25
05/25
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
PRO1160-001, NCT05721222: PRO1160 for Advanced Solid and Liquid Tumors

Recruiting
1/2
134
US, RoW
PRO1160
ProfoundBio US Co.
Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
11/26
03/27
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT04677855: Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Terminated
1
7
US, RoW
PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone
Pellficure Pharmaceuticals, Inc
Prostate Cancer
10/23
11/23
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
Rosen, Mark
NCT04876846: Trans-abdominal Fetal Pulse Oximetry; Tissue Light Scattering and Signal Integrity

Recruiting
N/A
10
US
GEN 3 Monitoring of Fetus
Raydiant Oximetry, Inc.
Fetal Hypoxia
04/25
04/25
Snyder, Peter
LINC6, NCT05382156: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Active, not recruiting
N/A
206
Europe, US
Osilodrostat, Isturisa
RECORDATI GROUP
Endogenous Cushing's Syndrome
06/27
08/27
Kumar, Pallavi P
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
Burger, Robert
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
NCT06517433: First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Completed
1
62
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
07/21
07/21
NCT06517485: First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

Completed
1
142
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma
05/22
08/22
NCT04396340: First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Terminated
1
31
US
XMT-1592
Mersana Therapeutics, IQVIA Biotech
Ovarian Cancer, Nonsmall Cell Lung Cancer
09/22
09/22
UPGRADE, NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Terminated
1
31
US
XMT-1536 (Upifitamab Rilsodotin), XMT-1536, UpRi, Carboplatin
Mersana Therapeutics, IQVIA Biotech, PSI CRO
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
10/23
10/23
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
NCT01191151: Web Based Orthopaedic Sports Medicine Registry

Terminated
N/A
12500
Europe, Canada, US, RoW
Arthrex, Inc.
Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
07/23
07/23
Stadtmauer, Edward
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
Soulen, Michael C
NCT02764801: Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Completed
3
131
US
Ultrasound contrast agent (Contrast-enhanced ultrasound), Definity (Lantheus Medical Imaging), Microbubble contrast agent, Logiq E9 Scanner (Contrast-enhanced ultrasound), Ultrasound Scanner
Sidney Kimmel Cancer Center at Thomas Jefferson University, University of California, San Diego, Vanderbilt University Medical Center, National Institutes of Health (NIH), Lantheus Medical Imaging, GE Healthcare, National Cancer Institute (NCI)
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
12/21
02/23
NCT02724540: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

Completed
2
162
Europe, Canada, US, RoW
Bland Embolization, BE, Transarterial chemoembolization, TACE, Drug Eluting Beads Embolization, DEB
Abramson Cancer Center at Penn Medicine, Guerbet
Neuroendocrine Tumor, Malignant, Liver Metastases
04/24
11/24
NCT02174549: Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Recruiting
1/2
25
US
Tirapazamine, Conventional Transarterial Embolization (TAE), TAE conducted with Lipiodol and Surgifoam as the embolizing agents.
Teclison Ltd.
Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
12/25
12/25
TACE-Ax-HCQ, NCT04873895: TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

Terminated
1
5
US
Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
Abramson Cancer Center at Penn Medicine, Pfizer
Colorectal Neoplasms Malignant
04/24
04/24
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

Active, not recruiting
N/A
100
US
Resin microspheres containing yttrium-90 (Y-90)
Sirtex Medical, Bright Research Partners
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
10/25
12/26
Foster, Gary
NCT05758883: Post-approval Follow-up Study of the IC-8 Apthera Intraocular Lens (IOL)

Completed
N/A
196
US
AcuFocus, Inc.
Cataract, Presbyopia
02/24
02/24
Sheline, Yvette I
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Kim, Edward S
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
VIRAGE, NCT05673811: Study of Nab-Paclitaxel and Gemcitabine and Plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Active, not recruiting
2
96
Europe, US
Nab-paclitaxel, Gemcitabine, VCN-01
Theriva Biologics SL
Pancreatic Adenocarcinoma, Metastatic
04/25
04/25
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT03695250: BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Terminated
1/2
8
US
IDO1 Inhibitor BMS-986205, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Edward Kim, Bristol-Myers Squibb, National Cancer Institute (NCI)
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
11/20
03/21
ARYA-1, NCT04502082: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma

Terminated
1/2
6
US
ET140203 autologous T cell product
Eureka Therapeutics Inc.
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
06/23
06/23
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
Montaner, Luis J
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22
NCT05418790: A Pilot Study to Evaluate Alternative Viral Load Tests During Start of Antiretroviral Therapy

Not yet recruiting
N/A
15
NA
TASSO device
Luis Montaner, Merck Sharp & Dohme LLC
HIV-1-infection
08/23
09/23
Feigenberg, Steven
NCT05302817: Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

Recruiting
1
20
US
Hyperpolarized xenon MRI
Xemed LLC, University of Pennsylvania
Carcinoma, Non-Small-Cell Lung
08/27
08/27
Sterman, Daniel H
LuTK02, NCT04495153: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting
2
90
US
Aglatimagene besadenovec, CAN-2409, AdV-tk
Candel Therapeutics, Inc., NYU Langone Health
Non Small Cell Lung Cancer
12/24
12/26
Quillen, Karen
ABA3, NCT04380740: Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

Recruiting
2
160
US
Placebo, saline, Abatacept, orencia
Boston Children's Hospital, Bristol-Myers Squibb
Graft Vs Host Disease
04/25
04/25
NCT04801797: Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Recruiting
2
172
US
Cytarabine, Ara-C, Arabinosylcytosine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Vyxeos, Venetoclax, Venclexta, Azacitidine, Vidaza
Massachusetts General Hospital, AbbVie
Acute Myeloid Leukemia
01/25
01/26
Domchek, Susan
MEDIOLA, NCT02734004 / 2015-004005-16: A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Checkmark In combination with Lynparza and Avastin for Ovarian cancer
Nov 2022 - Nov 2022: In combination with Lynparza and Avastin for Ovarian cancer
Checkmark From MEDIOLA trial in combination with olaparib in patients with germline BRCA-mutated mBC
Aug 2020 - Aug 2020: From MEDIOLA trial in combination with olaparib in patients with germline BRCA-mutated mBC
Checkmark From MEDIOLA trial in combination with durvalumab in patients with germline BRCA-mutated mBC
More
Active, not recruiting
1/2
264
Europe, US, RoW
Olaparib, MEDI4736, Bevacizumab, Avastin
AstraZeneca, Iqvia Pty Ltd
Ovarian, Breast, SCLC, Gastric Cancers
09/21
09/25
NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Recruiting
1
44
US
INO-5401, INO-9012, Cellectra 2000
University of Pennsylvania, Inovio Pharmaceuticals
BRCA1/2 Mutation
12/25
12/25
Yanik, Gregory
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
NCT05922761: BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting
2
45
US
Belumosudil, Rezurock, KD025, 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, C26H24N6O2, Fluticasone, Fluticasone Propionate, Azithromycin, Zithromax, Prednisone, Montelukast, Singulair
Dana-Farber Cancer Institute, Sanofi, National Heart, Lung, and Blood Institute (NHLBI)
Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
06/26
12/26
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
10/25
11/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Liu, Minetta C
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
TBCRC 050, NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Active, not recruiting
1/2
46
US
Niraparib, formerly MK-4827, Trastuzumab
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Tesaro, Inc., Susan G. Komen Breast Cancer Foundation, Breast Cancer Research Foundation of Alabama, The V Foundation
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
11/26
12/26
Iyer, Renuka
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
NCI-2018-02122, NCT03736720: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Terminated
2
11
US
Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Liposomal Irinotecan, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Quality-of-Life Assessment, Quality of Life Assessment
Roswell Park Cancer Institute, Ipsen
Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma, Refractory Digestive System Neuroendocrine Carcinoma, Refractory Pancreatic Neuroendocrine Carcinoma, Unresectable Digestive System Neuroendocrine Carcinoma, Unresectable Pancreatic Neuroendocrine Carcinoma
10/22
08/24
ARYA3, NCT04864054: T-Cell Therapy (ECT204) in Adults With Advanced HCC

Recruiting
2
30
US, RoW
ECT204 T cells, Regorafenib (STIVARGA®, BAY73-4506)
Eureka Therapeutics Inc.
Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
12/26
12/26
NCT05420636: Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Hourglass Sep 2022 - Dec 2022 : First-patient-in of trial for r/r SCLC and extrapulmonary high grade neuroendocrine tumors
Recruiting
2
42
US
Iadademstat, Paclitaxel
Fox Chase Cancer Center, Oryzon Genomics S.A.
Small-cell Lung Cancer, Neuroendocrine Carcinoma
08/25
08/26
ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting
2
122
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/26
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated
2
6
US
Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin
Aiwu Ruth He, MD, Georgetown University, Genentech, Inc.
Hepatocellular Carcinoma
06/23
06/23
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
NCT03211416: Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Active, not recruiting
1/2
37
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
Roswell Park Cancer Institute, Merck Sharp & Dohme LLC
Advanced Adult Hepatocellular Carcinoma, Child-Pugh Class A, Stage III Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IV Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
03/23
12/24
Specks, Ulrich
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting
3
160
Europe, Canada, Japan, US, RoW
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis
10/25
11/25
NCT05376319: PR3-AAV Resilient Remission or PRRR

Terminated
2
6
US
Obinutuzumab, Rituximab
Mayo Clinic, Genentech, Inc.
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
05/24
05/24
NCT00315380: Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Recruiting
N/A
700
Canada, US
University of Pennsylvania, GlaxoSmithKline, AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
12/28
12/28
Lasky, Joseph L
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
RedeS, NCT03037164: INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Recruiting
3
800
US
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Cerus Corporation
Anemia
10/25
01/26
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Kurman, Michael
NCT04886622: A Study of DT2216 in Relapsed/Refractory Malignancies

Completed
1
20
US
DT2216
Dialectic Therapeutics, Inc
Solid Tumor, Hematologic Malignancy
11/23
11/23
NCT04319757: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Completed
1
12
US, RoW
ACE1702, Cyclophosphamide, Fludarabine
Acepodia Biotech, Inc.
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
07/24
07/24
Levine, Lisa
NCT02661048: CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation

Completed
N/A
5
US
CyberHeart System
Varian, a Siemens Healthineers Company
Tachycardia, Ventricular
07/23
07/23
Perlis, Michael
NCT05838430: Solriamfetol and CBT-I in Patients With Insomnia Disorder

Recruiting
4
60
US
Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
University of Pennsylvania, Axsome Therapeutics, Inc.
Insomnia
07/25
12/25
Zeuzem, Stefan
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Terminated
1/2
135
Europe, RoW
ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
10/24
10/24
NCT04721665: German SLD-Registry (Deutsches SLD-Register)

Recruiting
N/A
5000
Europe
Leberstiftungs-GmbH Deutschland
Steatotic Liver Disease
11/26
11/36
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Konkle, Barbara A
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
Anderson, Allen
NCT02123706: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology

Recruiting
2a
20
US
Human Allogeneic Mesenchymal Stem Cells, Mesenchymal Stem Cells, Marrow Stromal Cells, Placebo, Lactated Ringer's Solution
Stemedica Cell Technologies, Inc., CardioCell, LLC; A Stemedica Company
Non-ischemic Heart Failure
06/16
06/16
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
Flaherty, Kevin R
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
 

Download Options